HomeCompareSNP vs ABBV

SNP vs ABBV: Dividend Comparison 2026

SNP yields 126.18% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SNP wins by $10.66M in total portfolio value
10 years
SNP
SNP
● Live price
126.18%
Share price
$45.66
Annual div
$57.61
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$10.76M
Annual income
$4,205,286.06
Full SNP calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SNP vs ABBV

📍 SNP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNPABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNP + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNP pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNP
Annual income on $10K today (after 15% tax)
$10,724.90/yr
After 10yr DRIP, annual income (after tax)
$3,574,493.15/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SNP beats the other by $3,553,437.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNP + ABBV for your $10,000?

SNP: 50%ABBV: 50%
100% ABBV50/50100% SNP
Portfolio after 10yr
$5.43M
Annual income
$2,115,028.91/yr
Blended yield
38.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SNP
Analyst Ratings
1
Hold
Consensus: Hold
Price Target
$41.09
-10.0% upside vs current
Range: $41.09 — $41.09
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNP buys
0
ABBV buys
0
No recent congressional trades found for SNP or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNPABBV
Forward yield126.18%3.06%
Annual dividend / share$57.61$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$10.76M$102.3K
Annual income after 10y$4,205,286.06$24,771.77
Total dividends collected$9.83M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$41.09$256.15

Year-by-year: SNP vs ABBV ($10,000, DRIP)

YearSNP PortfolioSNP Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$23,318$12,617.53$11,550$430.00+$11.8KSNP
2$52,446$27,496.23$13,472$627.96+$39.0KSNP
3$113,916$57,798.84$15,906$926.08+$98.0KSNP
4$239,220$117,329.72$19,071$1,382.55+$220.1KSNP
5$486,235$230,269.59$23,302$2,095.81+$462.9KSNP
6$957,694$437,423.01$29,150$3,237.93+$928.5KSNP
7$1,829,923$805,190.53$37,536$5,121.41+$1.79MSNP
8$3,395,892$1,437,874.20$50,079$8,338.38+$3.35MSNP
9$6,127,385$2,493,779.76$69,753$14,065.80+$6.06MSNP
10$10,761,588$4,205,286.06$102,337$24,771.77+$10.66MSNP

SNP vs ABBV: Complete Analysis 2026

SNPStock

China Petroleum & Chemical Corporation, an energy and chemical company, engages in the oil and gas and chemical operations in Mainland China, Singapore, and internationally. It operates through five segments: Exploration and Production, Refining, Marketing and Distribution, Chemicals, and Corporate and Others. The company explores and develops oil fields; produces crude oil and natural gas; processes and purifies crude oil; and manufactures and sells petroleum products. It also owns and operates oil depots and service stations; and distributes and sells refined petroleum products, including gasoline and diesel through wholesale and retail sales networks. In addition, the company manufactures and sells petrochemical and derivative petrochemical products; and other chemical products, such as basic organic chemicals, synthetic resins, synthetic fiber monomers and polymers, synthetic fibers, synthetic rubber, and chemical fertilizers. Further, it is involved in the exploration, production, and sale of petroleum and natural gas; production, storage, and sale of petrochemical and coal chemical products; import and export of petroleum products, natural gas, petrochemical, and chemical products; production and sale of catalyst products, lubricant base oil, polyester chips and fibers, plastics, and intermediate petrochemical products; research, development, production, and sale of ethylene and downstream byproducts; provision of geophysical exploration, drilling, survey, logging, downhole operational services, and construction services, as well as crude oil jetty services and natural gas pipeline transmission services; manufacturing production equipment; and coal chemical industry investment management activities. The company was incorporated in 2000 and is headquartered in Beijing, China. China Petroleum & Chemical Corporation is a subsidiary of China Petrochemical Corporation.

Full SNP Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SNP vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNP vs SCHDSNP vs JEPISNP vs OSNP vs KOSNP vs MAINSNP vs JNJSNP vs MRKSNP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.